 FOSTER CITY, Calif.--BUSINESS WIRE--Geron Corporation Nasdaq: GERN, a late-stage clinical biopharmaceutical company, today announced that ten abstracts containing clinical data and analyses related to imetelstat, the Companys first-in-class telomerase inhibitor, have been accepted for presentation at the 62nd American Society of Hematology ASH Annual Meeting to be held online from December 5-8, 2020. The abstracts are available on the ASH website at We are pleased th 